JAK Monotherapy Shows Efficacy in RA Review - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

JAK Monotherapy Shows Efficacy in RA Review

A systematic review found Janus kinase inhibitor monotherapy improved outcomes vs methotrexate or placebo, but direct comparisons with combination therapy were limited.

  • By

  • Andrea Surnit

  • May 22, 2026

  • 4 min

Share

Objective:

To evaluate the efficacy of Janus kinase inhibitors (JAKi) monotherapy in patients with rheumatoid arthritis compared to methotrexate or placebo.

Key Findings:
  • JAKi monotherapy showed improved clinical, functional, and radiographic outcomes compared to methotrexate or placebo.
  • Upadacitinib monotherapy achieved higher ACR 50% response rates at week 12 compared to methotrexate in methotrexate-naive patients.
  • Baricitinib monotherapy demonstrated higher ACR 20% response rates compared to placebo.
  • Filgotinib showed efficacy as both monotherapy and in combination therapy, with favorable outcomes compared to methotrexate alone.
Interpretation:

Limitations:
  • Variability in trial design, populations, treatment regimens, follow-up duration, and outcome measures.
  • Most studies did not directly compare JAKi monotherapy with combination therapy.
  • Older patients and those with elevated cardiovascular risk were underrepresented.
  • Most trials were industry-sponsored, potentially introducing reporting bias.
Conclusion:

Original Source(s)

JAK Monotherapy Shows Efficacy in RA Review

  • by Andrea Surnit

  • May 22, 2026

Related Content

Hair Repigmentation Reported With Baricitinib in Canities Subita

A single case suggests a possible benefit, but confounding factors and the off-label setting temper the conclusions.

Identification of ferroptosis hub gene cDKN1A relating to immune microenvironment in rheumatoid arthritis via bioinformatic analysis and experimental verification

Joint Site May Influence RA Treatment Response

A Swiss registry study found that the wrist and second and third metacarpophalangeal joints consistently resolved more slowly than most other joints following biologic or targeted synthetic therapy.